Whalesbook
Pharma Earnings Decline
The fourth-quarter earnings season delivered a difficult picture for several pharmaceutical players on May 13, 2026. Dr. Reddy's Laboratories reported a sharp 86.2% year-on-year drop in net profit to ₹220.1 crore, with revenue down 11.6%. This was due to factors like a significant shelf stock adjustment and price erosion in key markets. Other companies also saw profit declines: Tata Power Company's profit fell 4.5% to ₹995.9 crore, and revenue declined 12.8%. Torrent Power faced an even steeper profit drop of 70% to ₹318.2 crore, despite a small revenue dip. Nazara Technologies, a gaming firm, saw profits jump to ₹55.7 crore, but its revenue fell 23.5%. These results highlight challenges in the pharma sector, made worse by patent expirations and competition. The overall Indian pharma market grew 10.5% in Q4 FY26, thanks to chronic and specialty drugs, but this growth increasingly depends on price increases, not just volume.
Infrastructure Wins Big Orders
Unlike the struggling pharma sector, infrastructure and manufacturing companies won significant orders, boosting their growth outlook. Rail Vikas Nigam (RVNL) was the lowest bidder for a ₹221.3 crore Engineering, Procurement, and Construction (EPC) project from South East Central Railway. This continues a trend of strong orders for railway public sector units, with RVNL's order book offering good visibility for future revenue. Texmaco Rail & Engineering received a large Letter of Award worth ₹4,045 crore from Tsiko Africa Logistics for rolling stock and locomotives. This shows strong demand for rolling stock and puts Texmaco on track for growth. Its P/E ratio stands at 30.30. Interarch Building Solutions also contributed to the sector's momentum with a ₹102 crore contract for pre-engineered steel buildings.
Corporate News and Valuations
Other corporate news added to market activity. PNC Infratech resolved a dispute with the National Highways Authority of India for ₹234.99 crore. Vodafone Idea's board met to discuss Q4 results and possible fundraising. United Breweries received positive news as a ₹275 crore tax demand was cancelled. Valuations showed a mixed view. Dr. Reddy's Laboratories trades at a P/E of approximately 19.39 or 17.46, with analysts mostly rating it a 'Hold', though one gives a 'Strong Buy'. Tata Power's P/E is around 30.32 or 35.33, while Torrent Power's P/E ranges from 26.88 to 32.60 or 31.1, suggesting they are valued for growth. Nazara Technologies, despite lower revenue, has a P/E of 36.06 or a negative P/E of -10.75, possibly due to speculation or past losses. RVNL's P/E is notably high at 61.23 or 53.9, showing strong growth expectations.
Risks and Market Sentiment
Despite strong orders in infrastructure, risks remain. The pharma sector faces ongoing margin pressure. Dr. Reddy's Q4 was hit hard by lower Lenalidomide sales, price drops in North America and Europe, and a ₹453 crore stock adjustment. This shows sensitivity to specific products and markets. For infrastructure firms like RVNL, the high P/E of 61.23 suggests much future growth is already priced in, making it vulnerable to any project delays or fewer new orders. Historically, RVNL's P/E averaged 18.8 over five years, meaning its current valuation is much higher. Market sentiment on May 12, 2026, was also weak, with the Nifty 50 down 1.83% due to foreign investor selling and economic worries. This suggests strong company news may struggle to make an impact when investors are risk-averse. Dr. Reddy's has also seen analyst downgrades and worries about its biosimilar pipeline and trial issues.
Outlook for Sectors
Looking ahead, the Indian stock market remains sensitive to economic factors like oil prices and currency swings, with foreign investor selling increasing recently. While infrastructure's orders offer a clear path for growth, pharma's recovery depends on new product launches and better margins. Analyst views on Dr. Reddy's are mixed, with some rating it 'Hold' and others 'Strong Buy', reflecting differing opinions on its future prospects. The market expects ongoing volatility as earnings and global events unfold.